| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sulfathiazole sodium targets bacterial para-aminobenzoic acid (PABA) as a competitive inhibitor. It also targets the steroidogenic pathway as an endocrine disruptor, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRNA expression of CYP17, CYP19, and 3β-HSD. The compound increases the production of 17β-estradiol (E2).
|
|---|---|
| ln Vitro |
In vitro, sulfathiazole sodium is a competitive inhibitor of bacterial PABA. It enhances the activity of CYP19 in human adrenal cancer cells (H295R) and upregulates the mRNA expression of CYP17, CYP19, and 3β-HSD. It increases the production of 17β-estradiol (E2). The compound also acts as a cathodic corrosion inhibitor, inhibiting the corrosion of copper by chloride ions through chemical and physical adsorption on the copper surface.
|
| ln Vivo |
In vivo, sulfathiazole sodium has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish. It was used clinically as an oral and topical antibiotic for the treatment of bacterial infections. The compound is no longer commonly used in humans due to the availability of less toxic alternatives.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for sulfathiazole sodium typically involve studying its competitive inhibition of bacterial PABA. The compound is incubated with bacterial enzyme preparations in the presence of PABA, and the inhibition of enzyme activity is measured. Steroidogenic enzyme activity is assessed using H295R human adrenal cancer cells treated with the compound.
|
| Cell Assay |
In vitro cell-based assays for sulfathiazole sodium typically employ H295R human adrenal cancer cells. Cells are cultured and treated with various concentrations of the compound. Steroidogenic enzyme activity (CYP17, CYP19, 3β-HSD) is assessed by measuring mRNA expression levels via qPCR. Estradiol production is measured by ELISA or radioimmunoassay.
|
| Animal Protocol |
In vivo animal studies with sulfathiazole sodium have been conducted in aquatic organisms such as the Japanese medaka fish to assess endocrine disrupting effects. The compound was also studied in rats for its toxicological effects. However, specific study protocols are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of sulfathiazole sodium indicate it is orally active. As a short-acting sulfa drug, it is absorbed from the gastrointestinal tract and distributed throughout the body. Specific PK parameters such as half-life, Cₘₐₓ, and bioavailability have not been detailed in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of sulfathiazole sodium has been characterized in animal studies. Lesions were observed in rats given sulfathiazole in purified diets. The compound has endocrine disrupting effects. It is no longer used in humans due to the availability of less toxic alternatives. The compound is intended for research use only.
|
| References |
|
| Additional Infomation |
Sulfathiazole sodium is a sulfonamide drug. It is a sulfathiazole compound used as a short-acting anti-infective agent. Due to its toxicity, it is no longer commonly used for systemic treatment, but it can still be used topically in combination with other drugs to treat vaginal and skin infections, and it remains in use in veterinary medicine.
Sulfathiazole sodium is a research-grade sulfonamide antibiotic used in biological studies. It is not an approved therapeutic drug for current human use. The compound is supplied as a white crystalline powder with purity ≥99%. Synonyms include Sulfathiazole sodium salt and ST-Na. |
| Molecular Formula |
C9H8N3NAO2S2
|
|---|---|
| Molecular Weight |
277.3
|
| Exact Mass |
276.995
|
| CAS # |
144-74-1
|
| Related CAS # |
Sulfathiazole;72-14-0;Sulfathiazole-d4;1020719-89-4
|
| PubChem CID |
12285822
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
479.5ºC at 760mmHg
|
| Melting Point |
175ºC (form a); 202ºC (form b)
|
| Flash Point |
243.8ºC
|
| Vapour Pressure |
2.35E-09mmHg at 25°C
|
| LogP |
3.046
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
326
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(C1=CC=C(N)C=C1)([N-]C2=NC=CS2)=O.[Na+]
|
| InChi Key |
GWIJGCIVKLITQK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N3O2S2.Na/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9;/h1-6H,10H2;/q-1;+1
|
| Chemical Name |
sodium;(4-aminophenyl)sulfonyl-(1,3-thiazol-2-yl)azanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~140 mg/mL (~504.87 mM)
H2O : ~140 mg/mL (~504.87 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (36.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6062 mL | 18.0310 mL | 36.0620 mL | |
| 5 mM | 0.7212 mL | 3.6062 mL | 7.2124 mL | |
| 10 mM | 0.3606 mL | 1.8031 mL | 3.6062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
